Latest From Oncorus Inc.
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Oncorus Inc.
- Senior Management
Theodore T Ashburn, MD, PhD, Pres. & CEO
Christophe Queva, PhD, CSO
Stephanie Duncanson, PhD, Dir., Corp. Strategy & Bus. Dev.
- Contact Info
Phone: (857) 320-6400
50 Hampshire St.
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.